C - Chemistry – Metallurgy – 40 – B
Patent
C - Chemistry, Metallurgy
40
B
C40B 50/14 (2006.01) C12Q 1/68 (2006.01) C40B 30/04 (2006.01) C40B 40/06 (2006.01) C12P 19/34 (2006.01)
Patent
CA 2723984
The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
La présente invention porte sur des procédés et des compositions pour faciliter la détermination selon laquelle un cancer exprimant EGFR dans un individu est ou non un cancer sensible à un inhibiteur de EGFR, ainsi que sur des procédés pour déterminer la probabilité selon laquelle patient ayant un cancer exprimant EGFR présentera une réponse bénéfique à une thérapie par un inhibiteur de EGFR. Les procédés impliquent généralement la détermination d'un taux d'expression normalisé d'un produit de gène qui se corrèle à une sensibilité à un inhibiteur de EGFR.
Baker Joffre B.
Ford Shirin K.
Maddala Tara
Mauro David J.
Shak Steven
Bristol-Myers Squibb Company
Genomic Health Inc.
Smart & Biggar
LandOfFree
Predictors of patient response to treatment with egf... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Predictors of patient response to treatment with egf..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Predictors of patient response to treatment with egf... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1400073